CN115124500B - 一种精制多塞平的方法 - Google Patents
一种精制多塞平的方法 Download PDFInfo
- Publication number
- CN115124500B CN115124500B CN202210944305.2A CN202210944305A CN115124500B CN 115124500 B CN115124500 B CN 115124500B CN 202210944305 A CN202210944305 A CN 202210944305A CN 115124500 B CN115124500 B CN 115124500B
- Authority
- CN
- China
- Prior art keywords
- doxepin
- distillation tower
- product
- crude
- refining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005426 doxepin Drugs 0.000 title claims abstract description 31
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000007670 refining Methods 0.000 title claims abstract description 11
- 238000004821 distillation Methods 0.000 claims abstract description 23
- 238000010992 reflux Methods 0.000 claims abstract description 11
- 238000003379 elimination reaction Methods 0.000 claims abstract description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000002351 wastewater Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 8
- 229960002861 doxepin hydrochloride Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012067 demethylated product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
Abstract
本发明公开一种多塞平的精制方法,包括以下步骤将多塞平羟基物置于酸水中加热进行消除反应,反应完成后将反应液调节至中性,静置分层得油状粘稠的多塞平粗品,多塞平粗品在蒸馏塔中升温至290~300℃;维持所述蒸馏塔内为真空环境;控制所述蒸馏塔的塔顶全回流20min以上;调节所述蒸馏塔的塔顶回流比为4:1~5:1;收集所述蒸馏塔的塔顶280~285℃的馏分,即得精制的多塞平。本发明操作简单,同时避免了常规酸碱调节萃取的精制方式产生的大量含盐废水,更加绿色环保。
Description
技术领域
本发明涉及化学合成领域,具体涉及一种精制多塞平的方法。
背景技术
抑郁症是世界第四大疾病,抑郁症的发病已开始出现低龄(大学,乃至中小学生群体)化趋势。由于现代社会青年群体生活节奏的加快及工作压力的增加,以及老年人睡眠质量差,导致患有睡眠障碍的人群逐年递增,睡眠健康也成了一个不容忽视的问题。
盐酸多塞平最初是用于治疗抑郁症及焦虑性神经症的药,其作用在于抑制中枢神经系统对5-羟色胺及去甲肾上腺素的再摄取,从而使突触间隙中这二种神经递质浓度增高而发挥抗抑郁作用,也具有抗焦虑和镇静作用。随着该品临床使用发现,低剂量的盐酸多塞平对改善睡眠也能起到良好的效果。盐酸多塞平口服吸收好,生物利用度为13~45%,主要在肝脏代谢,活性代谢产物为去甲基化物,代谢物自肾脏排泄。
盐酸多塞平虽然是一个上市时间较久的药品,但是其在临床使用过程效果明显,所以仍被广泛使用。盐酸多塞平由多塞平与氯化氢成盐所得,所以多塞平的质量直接决定了盐酸多塞平的产品质量。常规的多塞平的精制方法都是通过酸、碱调盐后通过萃取精制,但此过程会产生大量的含盐废水,污水处理困难,所以开发一个新的精制多塞平的方法,具有重要的意义。
发明内容
针对上述现有技术的问题,本发明提供一种精制多塞平的方法,该方法利用高真空蒸馏的方法,通过调节蒸馏温度、塔顶回流比、接收馏分温度,来制备得到高纯度的多塞平,本发明操作简单,同时避免了常规酸碱调节萃取的精制方式产生的大量含盐废水,绿色环保。
为实现上述目的,本发明采用如下技术方案:
一种精制多塞平的方法,包括如下步骤:
(1)将多塞平粗品在蒸馏塔中升温至290~300℃;
(2)维持所述蒸馏塔内为真空环境;
(3)控制所述蒸馏塔的塔顶全回流20min以上;
(4)调节所述蒸馏塔的塔顶回流比为4:1~5:1;
(5)收集所述蒸馏塔的塔顶280~285℃的馏分,即得精制的多塞平。
优选的,所述多塞平粗品来自于多塞平羟基物消除反应工艺。所述多塞平粗品为粘稠的油状。
优选的,所述蒸馏釜还含有夹套,所述夹套中充有导热油。步骤(1)中,控制所述导热油的温度为300~320℃。
优选的,步骤(2)中所述的真空环境的真空度为2~3 mmHg。
采用本发明的方法精制的多塞平,其纯度为99.9%以上。
与现有技术相比,本发明操作简单,同时避免了常规酸碱调节萃取的精制方式产生的大量含盐废水,更加绿色环保。
具体实施方式
下面结合具体实施例对本发明的技术方案进行详细描述。
实施例1
在200升不锈钢蒸馏塔的塔釜内加入120kg多塞平粗品,开启导热油箱电加热机组,将导热油加热至300~320℃并开启不锈钢蒸馏塔的夹套循环,待釜内料液温度升温至290~300℃后,开启真空系统,维持塔内真空度在2~3mmHg,待塔顶温度达250℃以上后,先调节塔顶全回流20分钟,然后调节回流比为4:1,收集塔顶280~285℃的馏分,即得多塞平,纯度99.95%,收率87.6%。
实施例2
在500升不锈钢蒸馏塔的塔釜内加入340kg多塞平粗品,开启导热油箱电加热机组,将导热油加热至300~320℃并开启不锈钢蒸馏塔的夹套循环,待釜内料液温度升温至290~300℃后,开启真空系统,维持塔内真空度在2~3mmHg,待塔顶温度达250℃以上后,先调节塔顶全回流30分钟,然后调节回流比为5:1,收集塔顶280~285℃的馏分,即得多塞平,纯度99.94%,收率88.2%。
Claims (1)
1.一种精制多塞平的方法,其特征在于,包括如下步骤:
将多塞平粗品置于蒸馏塔中,所述蒸馏塔还含有夹套,所述夹套中充有导热油;控制所述导热油的温度为300~320℃,使得多塞平粗品升温至290~300℃;控制所述蒸馏塔内真空度为2~3 mmHg,先控制所述蒸馏塔的塔顶全回流20min以上,之后,调节所述蒸馏塔的塔顶回流比为4:1~5:1;收集所述蒸馏塔的塔顶280~285℃的馏分,即得精制的多塞平;
所述多塞平粗品来自于多塞平羟基物消除反应工艺;所述蒸馏塔为不锈钢材质。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944305.2A CN115124500B (zh) | 2022-08-08 | 2022-08-08 | 一种精制多塞平的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944305.2A CN115124500B (zh) | 2022-08-08 | 2022-08-08 | 一种精制多塞平的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115124500A CN115124500A (zh) | 2022-09-30 |
CN115124500B true CN115124500B (zh) | 2024-01-30 |
Family
ID=83385848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210944305.2A Active CN115124500B (zh) | 2022-08-08 | 2022-08-08 | 一种精制多塞平的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115124500B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3438981A (en) * | 1963-07-09 | 1969-04-15 | Boehringer & Soehne Gmbh | Dibenzooxepine and dibenzothiepine derivatives |
CN102924424A (zh) * | 2012-09-04 | 2013-02-13 | 苏州弘森药业有限公司 | 一种合成盐酸多塞平的方法 |
CN112724117A (zh) * | 2019-10-29 | 2021-04-30 | 南京济群医药科技股份有限公司 | 一种盐酸多塞平的精制方法 |
-
2022
- 2022-08-08 CN CN202210944305.2A patent/CN115124500B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3438981A (en) * | 1963-07-09 | 1969-04-15 | Boehringer & Soehne Gmbh | Dibenzooxepine and dibenzothiepine derivatives |
CN102924424A (zh) * | 2012-09-04 | 2013-02-13 | 苏州弘森药业有限公司 | 一种合成盐酸多塞平的方法 |
CN112724117A (zh) * | 2019-10-29 | 2021-04-30 | 南京济群医药科技股份有限公司 | 一种盐酸多塞平的精制方法 |
Non-Patent Citations (2)
Title |
---|
何志成.《化工原理》.中国医药科技出版社,2015,(第3版),第287-289页. * |
王锡玉 刘建中.《化工基础》.化学工业出版社,2000,(第2版),第244-246页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115124500A (zh) | 2022-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008538573A (ja) | ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用 | |
NO336948B1 (no) | 1,2-di(cyclisk)substituerte benzenforbindelser, medikament omfattende slike forbindelser, slike forbindelser for bruk som medikament og slike forbindelser for anvendelse i terapi for behandling av sykdom | |
JP2008538571A (ja) | ジヒドロベンゾフラン誘導体およびその使用 | |
JP2008538572A (ja) | ジヒドロベンゾフラン誘導体およびその使用 | |
CN102120720B (zh) | 盐酸芬戈莫德的合成新方法 | |
BR112015023334B1 (pt) | processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato | |
CN115124500B (zh) | 一种精制多塞平的方法 | |
US5089519A (en) | Aminomethyl-chroman compounds | |
US20170260164A1 (en) | Cd38 inhibitors and methods of treatment | |
US3987091A (en) | 11,12-secoprostaglandins | |
EP0061907B1 (en) | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | |
WO2006065706A1 (en) | N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto | |
Stork et al. | The Stereospecific Synthesis of dl-Alloyohimbane and dl-3-Epialloyohimbane1 | |
SONE et al. | Stereochemical Studies. XXVIII. Some Aspects of the Asymmetric Synthesis of (R)-(+)-4-Methyl-4-phenyl-2-cyclohexenone via an Enamine | |
EP0426416B1 (en) | Novel morpholinol compounds, their preparation and use | |
CN115850095A (zh) | 一种重酒石酸去甲肾上腺素的制备方法 | |
CA2123704C (en) | Methods and compositions utilizing pure s(+)isomer fluoxetine | |
CN104130239A (zh) | 度洛西汀手性中间体的制备方法 | |
EP1149083A1 (en) | Morpholinobenzamide salts | |
JPS61158971A (ja) | 2‐(アリルアルキルオキシメチル)モルフオリン誘導体、その製造方法およびそれを成分とする薬剤 | |
CN104862351A (zh) | 一种含共轭亚油酸的低热量结构脂质的制备方法及应用 | |
CN114380703B (zh) | 一种肾上腺素的精制方法 | |
CN112939806B (zh) | 一种卡比多巴的精制方法 | |
JP2013540768A (ja) | (6r)−テトラヒドロビオプテリン塩酸塩の製造方法 | |
CN109694384A (zh) | 一种胆碱酯酶抑制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |